Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maurice Jones

Physician Assistant, Medical Siloam Springs, AR Physician Assistant

NPI 1891894630 CMS profile 10714379

500 S Mount Olive St, Suite 200, Siloam Springs, AR 72761

Open in the dashboard

General payments

$2,473

102 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maurice Jones of Siloam Springs, AR is reported in the CMS Open Payments database as having received $2,473 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $219 12
2024 General $181 11
2023 General $397 15
2022 General $998 33
2021 General $678 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maurice Jones
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Maurice Jones were reported at $219. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Maurice Jones Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $678 $156 $41–$563 $132
2022 $998 $185 $55–$649 $149
2023 $397 $199 $58–$717 $160
2024 $181 $206 $62–$740 $164
2025 $219 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $626 21 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $584 33 payments
  3. Novo Nordisk Inc $426 7 payments
  4. Abbott Laboratories $185 10 payments
  5. Sanofi-Aventis U.S. LLC $156 4 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $74 4 payments
  7. Baxter Healthcare $69 1 payment
  8. Lilly USA, LLC $57 4 payments
  9. Exact Sciences Corporation $51 3 payments
  10. Horizon Therapeutics plc $44 2 payments
  11. Other $201 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,403 101 payments
  2. Debt forgiveness $69 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $592 19 payments
  2. JARDIANCE Diabetes $521 29 payments
  3. RYBELSUS $176 5 payments
  4. Ozempic $161 4 payments
  5. BREZTRI $150 5 payments
  6. TOUJEO $125 1 payment
  7. FreeStyle Libre $102 6 payments
  8. FreeStyle Libre 3 $83 4 payments
  9. Kerendia $74 4 payments
  10. JARDIANCE Diabetes $63 4 payments
  11. Other $646 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

2,588

Median for Physician Assistant: 241

Drug cost

$145,423

Median for Physician Assistant: $4,110

Branded share of claims

17.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 59 $54,627
Janumet Sitagliptin Phos/Metformin Hcl Brand 41 $40,743
Xarelto Rivaroxaban Brand 23 $11,920
Januvia Sitagliptin Phosphate Brand 15 $8,649
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 14 $6,066
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 52 $5,006
Symbicort Budesonide/Formoterol Fumarate Brand 11 $2,598
Atorvastatin Calcium Generic 325 $1,193
Mirtazapine Generic 27 $1,150
Albuterol Sulfate Hfa Albuterol Sulfate Brand 37 $1,136

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $57
$57 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $28
$28 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $16
$16 59 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $14
$14 — —
MOUNJARO
  • Lilly USA, LLC $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record